FDA extends Leqembi Iqlik review timeline following major amendment
BioArctic announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental Biologics License Application (sBLA) for Leqembi Iqlik (lecanemab-irmb).










